SRPT - Sarepta Therapeutics Inc

https://www.sarepta.com

Momentum: Bearish

Recent News

SRPT Stock Alert: Investors with Large Losses Should Contact Robbins LLP for Information About the Pending Lead Plaintiff Deadline in the Sarepta Therapeutics, Inc. Class Action - Sarepta Therapeutics ( NASDAQ:SRPT )

Benzinga • 2 weeks, 2 days ago • score: 0.16

SAN DIEGO, Aug. 29, 2025 ( GLOBE NEWSWIRE ) -- Robbins LLP reminds stockholders that a class action was filed on behalf of investors who purchased or otherwise acquired Sarepta Therapeutics, Inc. SRPT securities between June 22, 2023 and June 24, 2025.

Interval:

EMA1: EMA2:

AI Tools

Key Metrics

Trend: Downtrend

Source: Snapshot

Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapies, gene therapy, and other genetic therapeutic modalities for the treatment of rare diseases. The company is headquartered in Cambridge, Massachusetts.

52W High

$138.81

52W Low

$10.41

MA Status:

50D: Below 200D: Below

Beta (~1 neutral, <0.9 lower risk)

0.49

Valuation

Attractive

As of 2025-06-30 (Overview)

Trailing P/E (<15 better)

N/A

Forward P/E (<15 better)

7.25

EV/EBITDA (<8 favorable)

69.64

EV/Revenue (<3 favorable)

1.01

P/S (TTM) (<3 favorable)

0.79

P/B (<3 favorable)

1.44

Ownership

Institution‑heavy

Source: Overview

Insiders (1–5% typical)

4.16%

Institutions (25–75% balanced)

80.35%

Shares Outstanding

104,672,000

Float

88,269,000

Dividend Yield (2–6% sweet spot)

N/A

Ex‑Dividend Date

N/A

Income & Growth

Profitability: Weak

As of 2025-06-30 (Overview)

Revenue (TTM)

2,481,531,000

Gross Profit (TTM)

565,138,000

EPS (TTM)

-0.68

Profit Margin (>10% good)

-0.02%

Operating Margin (TTM) (higher better)

0.19%

ROE (TTM) (>15% strong)

-0.05%

EPS YoY (Quarterly) (>10% good)

26.64

Revenue YoY (Quarterly) (>8% good)

0.68

Momentum

Bearish momentum

Value

-0.4223

-0.3744

Trend

Falling

Signal Cross

No cross

As of

Sep. 12, 2025